Bioxytran (BIXT) Retained Earnings (2010 - 2026)
Bioxytran (BIXT) posted Retained Earnings of -$23.1 million for Q1 2026, down 226.29% sequentially from $18.3 million in Q4 2025, and down 232.57% YoY from $17.4 million in Q1 2025.
Bioxytran (BIXT) Retained Earnings (2010 - 2026) Analysis & Trends
Bioxytran has reported Retained Earnings for 17 years, with the latest figure at -$23.1 million in Q1 2026.
- Quarterly Retained Earnings fell 232.57% year-over-year to -$23.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$23.1 million (down 232.57% YoY) and the FY2025 annual result came in at $18.3 million, up 7.66% from the prior year.
- Retained Earnings slipped to -$23.1 million in Q1 2026 per BIXT's latest filing, from $18.3 million in the prior quarter.
- Over five years, Retained Earnings peaked at $18.3 million in Q4 2025 and troughed at -$23.1 million in Q1 2026.
- A 5-year average of $722066.4 and a median of $5.9 million in 2022 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 208.28% in 2024, down 293.05% in 2024.
- Over 5 years, Retained Earnings stood at $8.4 million in 2022, then tumbled by 286.96% to -$15.7 million in 2023, then jumped by 208.28% to $17.0 million in 2024, then advanced by 7.66% to $18.3 million in 2025, then plunged by 226.29% to -$23.1 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$23.1 million, $18.3 million, and $17.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - | -23.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.11 Mn |
| Dec 31, 2025 | 18.30 Mn |
| Sep 30, 2025 | 17.47 Mn |
| Jun 30, 2025 | 17.47 Mn |
| Mar 31, 2025 | 17.43 Mn |
| Dec 31, 2024 | 17.00 Mn |
| Sep 30, 2024 | -18.30 Mn |
| Jun 30, 2024 | -16.96 Mn |
| Mar 31, 2024 | -16.30 Mn |
| Dec 31, 2023 | -15.70 Mn |
| Sep 30, 2023 | -14.54 Mn |
| Jun 30, 2023 | 11.28 Mn |
| Mar 31, 2023 | 8.44 Mn |
| Dec 31, 2022 | 8.40 Mn |
| Sep 30, 2022 | -10.41 Mn |
| Jun 30, 2022 | 5.88 Mn |
| Mar 31, 2022 | 5.92 Mn |
| Dec 31, 2021 | -8.75 Mn |
| Sep 30, 2021 | -7.72 Mn |
| Jun 30, 2021 | 4.74 Mn |